IMRX Immuneering
- 1.800
- +0.030+1.69%
- 1.770
- -0.030-1.67%
Immuneering News
Immuneering | 8-K: Current report
Immuneering | 8-K: Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates - Topline data from the Phase 1 portion of Phase 1/2a trial of IMM-1-104 expected in March 2024 -
Immuneering | 8-K: Current report
Immuneering | 8-K: Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates -Dose evaluation portion of IMM-1-104 Phase 1/2a trial approximately two-thirds enrolled; Immuneering's recommendation for a Phase 2 dose expected in
Immuneering | 8-K: Current report
Immuneering | 8-K: Current report
Immuneering | 8-K: Current report
Immuneering | 8-K: Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
Immuneering | DEFA14A: Others
Immuneering | DEF 14A: Definitive proxy statements
Immuneering | 8-K: Current report
Immuneering | 8-K: Current report
Immuneering | 8-K: Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
Immuneering | 8-K: Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights
Immuneering: Current report (Amendment)
8-K/A | Immuneering Corp (0001790340) (Filer)
Immuneering | S-3: Registration statement for specified transactions by certain issuers
Immuneering | 8-K: Immuneering Reports Second Quarter 2022 Financial Results and Recent Business Highlights
Immuneering | 8-K: Current report
Immuneering | 8-K: Current report
Immuneering | 8-K: Immuneering Reports First Quarter 2022 Financial Results and Recent Business Highlights
Analysis
Price Target
No Data
